01—Abstract
Summary
Summary of the 10-K filed February 12, 2025. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reports that it is the largest buyer of biopharmaceutical royalties.
In 2024 it generated Portfolio Receipts of $2.8 billiona (versus $3.05 billion in 2023, a decline of $247.3 million, or 8.1%), driven by the absence of the $475.0 million Zavzpret milestone received in 2023. Royalty Receipts rose 13.1% to $2.77 billion, led by the cystic fibrosis franchise ($856.8 million), Trelegy ($283.7 million) and Evrysdi ($173.5 million). The company deployed $2.8 billion of capital in 2024, paid $376.5 million in dividends and repurchased $229.9 million of Class A shares.
Consolidated net income was $1.33 billionb, and net income attributable to Royalty Pharma plc was $858.98 million, down from $1.13 billion in 2023, largely reflecting a $732.5 million provision for changes in expected cash flows and expected credit losses. At year-end 2024, senior unsecured notes totaled $7.8 billion in principal, with $1.8 billion of revolving commitments available, and cash and cash equivalents were $929.0 million. Operating cash flow was $2.77 billion.
The company is externally managed, and in January 2025 it agreed to acquire its Manager, RP Management, LLC, for approximately $1.1 billionc, subject to shareholder approval and expected to close in the second quarter of 2025. The filing also flags risks including concentration (the top five franchises were 64% of Royalty Receipts), the accounting volatility of financial royalty assets, the Investment Company Act exemption, and tax treaty and Pillar Two developments.
02—Key points
Key Highlights
- Portfolio Receipts of $2.80 billion in 2024, down 8.1% from $3.05 billion, mainly because 2023 included a $475.0 million Zavzpret milestone; Royalty Receipts grew 13.1% to $2.77 billion.
- Net income attributable to Royalty Pharma plc fell to $858.98 million from $1.13 billion, with the provision for changes in expected cash flows rising to $732.5 million from $560.7 million.
- Capital deployment of $2.8 billion in 2024, including the $905 million Voranigo royalty and the $350 million Niktimvo and $150 million Yorvipath synthetic royalties.
- Shareholder returns in 2024 included $376.5 million of dividends ($0.21 per quarter) and $229.9 million of share repurchases.
- Senior unsecured notes of $7.8 billion at year-end 2024, a weighted average coupon of 3.06%, and $1.8 billion of undrawn revolving commitments; the company was in compliance with its financial covenants.
- Agreed in January 2025 to internalize its Manager for approximately $1.1 billion, with the transaction expected to close in Q2 2025 subject to shareholder approval.
- Vertex's cystic fibrosis franchise accounted for 36% of total income and other revenues in 2024, and the top five franchises represented 64% of Royalty Receipts.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 12, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $2.26B$2.35B | −3.9% |
| R&D Expenses | $2.00M$52.00M | −96.2% |
| Operating Expenses | $971.13M$862.40M | +12.6% |
| Operating Income | $1.29B$1.49B | −13.4% |
| Net Income | $858.98M$1.13B | −24.3% |
| EPS (Basic) | $1.92$2.54 | −24.4% |
| EPS (Diluted) | $1.91$2.53 | −24.5% |
| Shares Outstanding (Basic) | 448.19M447.60M | +0.1% |
| Shares Outstanding (Diluted) | 594.11M602.90M | −1.5% |
05—Questions
Frequently Asked Questions
Why did Portfolio Receipts decline in 2024 even though Royalty Receipts grew?
Portfolio Receipts fell $247.3 million to $2.80 billion, but Royalty Receipts rose $321.2 million to $2.77 billion. The decline was driven by milestones and other contractual receipts, which fell $568.5 million to $30.8 million, mainly because 2023 included a $475.0 million Zavzpret milestone payment.
What drove the increase in the provision for changes in expected cash flows?
The provision rose to $732.5 million from $560.7 million. The filing attributes the expense mainly to Evrysdi, due to declines in sell-side consensus sales forecasts, and to the cystic fibrosis franchise, including the inclusion of Alyftrek consensus estimates and a conservative assumption that deuterated ivacaftor is not royalty-bearing. Provision expense for credit losses was $100.4 million, primarily from the addition of Niktimvo.
What is the Internalization and how would it change the company?
In January 2025 Royalty Pharma agreed to acquire RP Management, LLC for about $1.1 billion, consisting of roughly 24.5 million RP Holdings shares, $380 million of the Manager's existing debt and $200 million of cash, less certain operating payments. If approved, the company would cease to be externally managed and its Manager's employees would become company employees. The filing expects this to reduce costs, increase shareholder alignment and simplify the structure, but it also notes added overhead and new liabilities.
What are the main risks to royalty cash flows highlighted in the filing?
The filing cites sales declines from pricing pressure, competition, generic or biosimilar entry, and loss of exclusivity; reliance on a limited number of products; marketers' control over commercialization; and US drug pricing policy, including the Inflation Reduction Act. It also highlights that royalty durations are estimates that may prove inaccurate, which could affect income and cause impairments.
How much debt does the company have and when does it mature?
Senior unsecured notes totaled $7.8 billion in principal at December 31, 2024. The current portion of long-term debt was $997.8 million, reflecting the $1.0 billion of 1.20% notes due September 2025. Scheduled principal payments are $1.0 billion in 2025, $1.0 billion in 2027, $500 million in 2029 and $5.3 billion thereafter. The company also had $1.8 billion of revolving commitments available.
06—Continue